-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Huaaotai Bio and Huabo Bio, the subsidiaries of Huahai Pharmaceutical, received the "Drug Clinical Trial Approval Notice" approved and issued by the State Drug Administration for HB0028 injection
HB0028 is a bispecific antibody targeting programmed death ligand 1 (PD-L1) and transforming growth factor-beta (TGF-beta)
In addition, the HB0028 project fused the TGF-β type II receptor with the C-terminus of the anti-PD-L1 antibody, which overcomes the problem that the fusion of the TGF-β type II receptor with the N-terminus of the anti-PD-L1 antibody is prone to produce O sugars.
At present, there are no similar drugs targeting both PD-L1 and TGF-β on the market